Back to articles
Comparative guide · 6 min read

Alpha-Lipoic Acid vs Acetyl-L-Carnitine — two mitochondrial cofactors compared

Updated 2026-05-13 · Reviewed by SupplementScore editors · No sponsorships

ALA (alpha-lipoic acid) and ALCAR (acetyl-L-carnitine) sit next to each other in the "mitochondrial support" aisle but solve different problems. ALA is best evidenced for diabetic peripheral neuropathy — particularly intravenous use in European trials — with mixed oral evidence. ALCAR is best evidenced for fatigue in older adults, mild cognitive impairment, and certain peripheral neuropathies (chemotherapy-induced, diabetic). Both are commonly combined in "mitochondrial stacks"; the rationale is reasonable but the trial evidence for the combination is much thinner than for each alone.

Quick verdict

GoalBetter choiceWhy
Diabetic peripheral neuropathy (symptomatic)ALA (with caveats)Multiple RCTs at 600 mg/day oral show symptomatic improvement; IV trials stronger than oral.
Chemotherapy-induced peripheral neuropathyALCAR — but with cautionALCAR has trial evidence; however, one large RCT in taxane-CIPN showed worsening, so coordinate with oncology.
Fatigue in older adults / centenariansALCARMalaguarnera trials show reduction in physical and mental fatigue at 2 g/day in elderly.
Mild cognitive impairment / early Alzheimer's adjunctALCARSeveral small trials; modest, inconsistent effect; reasonable adjunct.
Insulin sensitivity / glycaemic controlALA (modest)Small effects on HbA1c in meta-analysis; not a substitute for diabetes meds.
Antioxidant capacity / general "anti-aging"Neither shinesBoth have mechanism stories; neither has clean clinical antioxidant-endpoint trials in healthy adults.

How they actually work

ALA — a dithiol antioxidant and cofactor

Alpha-lipoic acid is a sulphur-containing cofactor for pyruvate and alpha-ketoglutarate dehydrogenase complexes in mitochondrial energy metabolism, and an antioxidant in both lipid and aqueous phases. It can regenerate vitamin C, vitamin E, and glutathione. Oral ALA has variable bioavailability; the R-enantiomer (R-ALA) has higher bioavailability than the racemic (R/S) form. Most older trials used IV racemic ALA at 600 mg, which produced cleaner neuropathy improvement than oral.

ALCAR — acetylated carnitine that crosses the blood-brain barrier

L-Carnitine shuttles long-chain fatty acids into mitochondria for beta-oxidation. The acetylated form (ALCAR) crosses the blood-brain barrier more readily and additionally donates an acetyl group that can feed into acetyl-CoA pools relevant to neurotransmitter synthesis (notably acetylcholine). Oral bioavailability of ALCAR is reasonable (~20%); tissue uptake into neurons is the relevant practical mechanism.

Diabetic neuropathy — both have evidence

ALA: ALADIN, SYDNEY, and NATHAN trials established ALA's role in symptomatic diabetic neuropathy. Oral 600 mg/day for ~5 weeks reduced pain, paresthesia, and numbness in several trials. The NATHAN 1 trial (4-year, oral 600 mg/day) showed improvement in nerve conduction measures and Neuropathy Impairment Score, though the primary composite endpoint was not significant.

ALCAR: separate trials at 1–3 g/day showed improvement in pain and nerve conduction in diabetic neuropathy. Mechanism may include support of nerve regeneration. Effect size is modest; tolerability is generally good.

Fatigue — ALCAR has the clearer signal

Trials in elderly with chronic fatigue, mild cognitive impairment, and centenarians (Malaguarnera and colleagues) consistently show 2 g/day ALCAR reduces fatigue scores and improves cognitive measures vs placebo over 6 months. ALA has no comparable fatigue-specific trial evidence.

Cognition — ALCAR's secondary niche

ALCAR has small trials in mild cognitive impairment and early Alzheimer's showing modest cognitive improvement; meta-analyses are inconsistent but trend positive. As an adjunct for early cognitive complaints in older adults, it has more direct evidence than ALA, but neither replaces evaluation and treatment for diagnosed dementia.

Insulin sensitivity — ALA's mechanism but small effect

Meta-analyses of ALA in type 2 diabetes show small HbA1c reductions (~0.3%) — not large enough to displace metformin or GLP-1 agonists, but plausibly useful as adjunct in users wanting marginal additional control.

Dose, form, and timing

ALA: 600 mg/day oral; can be racemic (R/S) or R-ALA (R-ALA at 300 mg is roughly equivalent to racemic 600 mg). Take 30 minutes before meals on an empty stomach for best absorption. Allow 4–8 weeks for neuropathy effect.

ALCAR: 1–3 g/day in divided doses with meals. Most fatigue and cognition trials use 1 g BID or 2 g/day. Effect develops over weeks. Generally well-tolerated; can be activating — avoid late-evening dosing.

Safety profile

ALA: well-tolerated. Rare hypoglycaemia in users on insulin or sulfonylureas — monitor glucose. Rare insulin-autoimmune syndrome reports (Asian populations, HLA-DRB1*04:06 carriers). Caution with hypothyroidism on levothyroxine (theoretical interference). Pregnancy: not adequately studied.

ALCAR: well-tolerated. Mild GI upset, occasional "fishy" body odour at high doses, occasional activation/agitation. Theoretical interaction with warfarin (case reports of altered INR). Avoid in dialysis without nephrologist input. The taxane-CIPN trial (Hershman et al 2013) is a real concern in chemotherapy contexts — discuss with oncology.

Practical rule. For symptomatic diabetic peripheral neuropathy, ALA 600 mg/day oral for a 6–8 week trial. For age-related fatigue, mild cognitive complaints, or both, ALCAR 1 g BID. Stacking is reasonable if both indications coexist, though the combination doesn't have RCT evidence above each one alone.

When neither is the right answer

If "neuropathy" is actually B12 deficiency, hypothyroidism, alcohol-related neuropathy, or compression neuropathy, treat the cause. Check B12, TSH, HbA1c, and review medications (chemotherapy, statins, fluoroquinolones, B6 toxicity from megadose supplements) before assuming a generic "mitochondrial support" frame. Persistent symptoms warrant neurology workup.

Who should pick each

Pick ALA if: diabetic peripheral neuropathy is the primary complaint, you have decent oral absorption and tolerate empty-stomach dosing, you're not on insulin or sulfonylurea without monitoring.

Pick ALCAR if: fatigue in older adult or post-illness recovery, mild cognitive complaints, diabetic neuropathy with prominent fatigue, you tolerate activating supplements.

What we'd actually buy

For diabetic peripheral neuropathy: ALA 600 mg/day 30 min before breakfast for 8 weeks, with glucose monitoring if on diabetes meds. For age-related fatigue plus mild cognitive complaints: ALCAR 1 g BID for 12 weeks, with morning + early-afternoon dosing to avoid sleep activation.

Sources

Read more: